Artiva Biotherapeutics (ARTV) vs Century Therapeutics (IPSC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Century Therapeutics (IPSC) has outperformed Artiva Biotherapeutics (ARTV) over the past year, gaining 137.8% versus a gain of 20.8%. Century Therapeutics is the larger company by market cap ($211.6 million vs $186.9 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARTV | IPSC |
|---|---|---|
| Share price | $3.78 | $1.17 |
| Market cap | $186.85M | $211.56M |
| 1-day change | -1.31% | -11.74% |
| YTD return | -11.89% | +17.09% |
| 1-year return | +20.77% | +137.76% |
| 5-year return | — | -93.23% |
| EPS (TTM) | $-2.85 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | $109.16M |
| Revenue growth (YoY) | -100.00% | +1556.76% |
| Net income (latest FY) | $-83.86M | $-9.58M |
| Operating margin | — | -15.82% |
| Net margin | — | -8.78% |
| 52-week high | $14.53 | $3.04 |
| 52-week low | $2.96 | $0.48 |
| Distance from 52-week high | -73.98% | -61.68% |
| Analyst consensus | buy | buy |
| Avg. price target upside | +448.94% | +307.73% |
| Average volume | 792.26K | 759.69K |
| Shares outstanding | 49.43M | 181.60M |
| Employees | 134 | 78 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- IPSC has outperformed ARTV by 117.0 percentage points over the past year.
- Century Therapeutics grew revenue faster in its latest fiscal year (+1556.76% vs -100.00%).
About Artiva Biotherapeutics
ARTV stock →Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. Its lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody -associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, and B-cell-non-Hodgkin lymphoma.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 134 employees
About Century Therapeutics
IPSC stock →Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 78 employees
ARTV vs IPSC FAQ
Which is bigger, Artiva Biotherapeutics or Century Therapeutics?
Century Therapeutics (IPSC) is larger, with a market capitalization of $211.56M compared with $186.85M for Artiva Biotherapeutics (ARTV).
Which stock has performed better over the past year, ARTV or IPSC?
IPSC returned +137.76% over the past 12 months, compared with +20.77% for ARTV (price return, excluding dividends). Past performance does not predict future results.
Are Artiva Biotherapeutics and Century Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.